- Poster presentation
- Open Access
PReS-FINAL-2259: Spectrum of Sjögren syndrome in children
© Bica et al.; licensee BioMed Central Ltd. 2013
- Published: 5 December 2013
- Parotid Gland
- Lacrimal Gland
- Minor Salivary Gland
Sjögren's syndrome is an autoimmune disease characterized by the presence of a lymphocytic infiltrate in the salivary and lacrimal glands, manifesting with xerostomia and xerophthalmia, which is more common in women between 30 and 50 years old, uncommon in children, with few cases reported in the literature.
To describe the clinical and laboratory presentation of pediatric patients with Sjögren's syndrome treated in primary Rheumatology Department of the Hospital Universitario Clementino Fraga Filho of the UniversidadeFederal of Rio de Janeiro, Brazil (HUCFF-UFRJ).
26 child and adolescent patients were selected with diagnosis of primary Sjögren's syndrome, treated in the Rheumatology Department of HUCFF-UFRJ. Patients were evaluated according to modified European criteria by the American-European Consensus (VITALI et al, 2002).
26 patients were included in the study: 20 girls (76%), 6 boys (24%), with mean age at diagnosis of 12.6 years (3-21 years). Patients were 16 years of age or younger at the onset of symptoms. Eight (30.7%) patients had parotid gland enlargement as the initial manifestation of the disease, with recurrent episodes in 2 (7.6%) patients. Ten (38%) had dry mouth complaint and 16 (62%) had ocular signs and symptoms, 18 patients (69%) had altered parotid ultrasonography, 19 patients (73%) had impaired salivary glandscintigraphy and 6 patients (23%) had abnormal parotid MRI. In 8 patients (30%) the minor salivary gland biopsy showed chronic sialadenitis compatible with Sjögren syndrome. The analysis of serum autoantibodies, showed 8 patients (30%) positive for rheumatoid factor, 10 patients (38%) with Anti-Ro, 9 patients (34%) with Anti-La, 9 patients (34.6%) Anti-Ro and Anti-la and 18 patients (69%) with antinuclear antibody (ANA). 12 patients (46%) had arthritis. 7 patients (26%) had CNS involvement. 3 patients (11.5%) had vascular compromise. One patient (3.8%) showed tachyarrhythmia, leucopenia in 2 patients (7.6%), hypergammaglobulinemia in 8 patients (30%) and hypogammaglobulinemia in 1 patient (3.8%). With regard to treatment, 25 patients (96%) received hydroxychloroquine. Azathioprine was used in 4 patients (15.3%), methotrexate in 12 patients (46%), human immunoglobulin in 1 patient (3.8%), cyclophosphamide in 2 patients (7.6%), leflunomide in 1 patient (3.8%) and rituximab 2 patients (7.6%).
This present study demonstrated the demographic, clinical, and therapeutic profile in a series of patients with Sjögren's syndrome in children and adolescents, a relatively rare condition, presenting an overview of this population in our hospital.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.